380 related articles for article (PubMed ID: 32748171)
21. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.
Moehler M; Delic M; Goepfert K; Aust D; Grabsch HI; Halama N; Heinrich B; Julie C; Lordick F; Lutz MP; Mauer M; Alsina Maqueda M; Schild H; Schimanski CC; Wagner AD; Roth A; Ducreux M
Eur J Cancer; 2016 May; 59():160-170. PubMed ID: 27039171
[TBL] [Abstract][Full Text] [Related]
22. The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.
Shi MY; Liu HG; Chen XH; Tian Y; Chen ZN; Wang K
Front Immunol; 2022; 13():1088886. PubMed ID: 36703971
[TBL] [Abstract][Full Text] [Related]
23. m
Peng C; Xiong F; Pu X; Hu Z; Yang Y; Qiao X; Jiang Y; Han M; Wang D; Li X
Front Immunol; 2023; 14():1326031. PubMed ID: 38187373
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint inhibitor therapy in locally advanced MSI GI malignancies.
Harrold EC; Keane F; Cercek A
Clin Adv Hematol Oncol; 2024 May; 22(4):162-173. PubMed ID: 38739719
[TBL] [Abstract][Full Text] [Related]
25. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.
Long J; Lin J; Wang A; Wu L; Zheng Y; Yang X; Wan X; Xu H; Chen S; Zhao H
J Hematol Oncol; 2017 Aug; 10(1):146. PubMed ID: 28774337
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in Gastrointestinal Malignancies.
Surana R; Pant S
Adv Exp Med Biol; 2021; 1342():259-272. PubMed ID: 34972968
[TBL] [Abstract][Full Text] [Related]
27. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
[TBL] [Abstract][Full Text] [Related]
28. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
29. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
Chen Y; Zheng X; Wu C
Front Immunol; 2021; 12():792691. PubMed ID: 34925375
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
Fazio N; Abdel-Rahman O
Curr Treat Options Oncol; 2021 Feb; 22(3):19. PubMed ID: 33559013
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous melanoma and the immunotherapy revolution (Review).
Leonardi GC; Candido S; Falzone L; Spandidos DA; Libra M
Int J Oncol; 2020 Sep; 57(3):609-618. PubMed ID: 32582963
[TBL] [Abstract][Full Text] [Related]
32. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
33. Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
Chau I
Clin Cancer Res; 2017 Oct; 23(20):6002-6011. PubMed ID: 28615369
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature.
Kamposioras K; Ntellas P; Nikolaou M; Germetaki T; Gazouli I; Dadouli K; Zarkavelis G; Amylidi AL; Tolia M; Mauri D
JNCI Cancer Spectr; 2021 Dec; 5(6):. PubMed ID: 34926989
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
36. [Research Progress in Immunosuppressive Tumor Microenvironment of Gastrointestinal Cancer].
Li YT; Tan XY; Huang LN; Ma LX; Fu L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Jan; 53(1):7-14. PubMed ID: 35048593
[TBL] [Abstract][Full Text] [Related]
37. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
39. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: Elements of a recipe for disaster.
Mishra AK; Singh SK; Dayanandan S; Banerjee S; Chakraborty S; Gopal AB; Samal S; Poirah I; Chakraborty D; Bhattacharyya A
Cytokine; 2022 Aug; 156():155917. PubMed ID: 35660715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
